IN-122517 / Korea Kolmar - LARVOL DELTA

A potent and highly selective HPK1 inhibitor as a combination strategy to improve the clinical response of the immune checkpoint inhibitor (AACR 2025) - "In the combination group, complete responses (CRs) were observed in a subset of animals, and re-challenge experiments confirmed the absence of tumor regrowth, indicating the establishment of an immune memory response. Tumor-infiltrating lymphocytes showed increased infiltration of T cells, natural killer (NK) cells, and dendritic cells (DCs), demonstrating the compound's potency in activating and recruiting immune effectors within the tumor microenvironment (TME).These data supported the nomination of IN-122517 into IND-enabling studies as a combination partner with Immune checkpoint inhibitors (ICIs)."

Checkpoint inhibition • Clinical • Oncology • IL2 • LCP2

HKinnoen Announces Research Results on HPK1 Inhibitor and EGFR Protein Degrader at AACR [Google translation] (BioTimes) - "At this conference, HK inno.N announced that IN-122517 showed high anticancer efficacy compared to monotherapy with anti-PD-1 antibody in a test using syngeneic models of colorectal cancer, and when administered together, the tumor achieved complete remission and showed a continuous immune memory response even after discontinuation of administration. IN-122517 is currently under development with the goal of applying for an investigational new drug (IND) in 2026."

IND • Preclinical • Colorectal Cancer